A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trail to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for Treatment of Acute Migraine in Sumatriptan Non-Responders.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trail to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for Treatment of Acute Migraine in Sumatriptan Non-Responders.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Rizatriptan (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 24 Jun 2010 Results have been presented in an abstract at the 52nd meeting of the American Headache Society.
    • 26 Jan 2010 Actual patient number (109) added as reported by ClinicalTrials.gov.
    • 26 Jan 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top